Compare AbCellera Biologics Inc (ABCL) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Diamondback Energy Inc — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Diamondback Energy Inc trades at $184.44 (market cap $50.79B). The key difference: Diamondback Energy Inc is far larger — about 21.6× AbCellera Biologics Inc's market cap, and Diamondback Energy Inc pays a 2.44% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | FANG | |
|---|---|---|
Market Cap | $2.35B | $50.79B |
Sector | Health | Energy |
52-Week High | $8.12 | $213.69 |
52-Week Low | $2.78 | $134.53 |
Enterprise Value | $1.99B | $64.52B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Diamondback Energy (FANG) trades at $180.56, up 4.95% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth to $14.93B in 2025 but faces declining net margins. Analyst consensus is overwhelmingly bullish with a $232.10 price target, supported by positive energy sector sentiment from Zacks and Seeking Alpha as of late June 2026.
FANG offers upside potential from high analyst targets and operational cash flow strength, but risks include volatile oil prices, margin compression, and technical resistance near $175. The stock's high P/E of 177.28 reflects growth expectations, yet execution on Q2 2026 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
